Form 4 for BGMS Bio Green Med Solution, Inc.
Accepted 2024-01-31 00:00:00 ET · period of report 2024-01-29 · accession 0001104659-24-008862 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-01-31 | 2024-01-29 | BGMS | SCHWARTZ BRIAN | Interim Chief Medical Off, Dir | A - Grant | $0.00 | +12.5K | 15.2K | +462% | $0 |
| D | 2024-01-31 | 2024-01-29 | BGMS | SCHWARTZ BRIAN | Interim Chief Medical Off, Dir | A - Grant | $0.00 | +12.5K | 12.5K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-01-29 | A | A | 12,500 | $0.00 | 15,205 | D | — | — | (F1) Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in equal monthly installments beginning on February 29, 2024, subject to the Reporting Person's continued service through the applicable vesting date. (F2) These securities were granted to Dr. Schwartz in connection with his appointment as interim Chief Medical Officer of Cyclacel Pharmaceuticals, Inc. |
| 2 | Derivative | Stock Option (right to buy) | 2024-01-29 | A | A | 12,500 | $0.00 | 12,500 | D | $2.28 · — to 2034-01-29 | 12,500 Common Stock | (F2) These securities were granted to Dr. Schwartz in connection with his appointment as interim Chief Medical Officer of Cyclacel Pharmaceuticals, Inc. (F3) The shares underlying the option vest in equal monthly installments beginning on February 29, 2024, subject to the Reporting Person's continued service through the applicable vesting date. |